Mark C Genovese, MD
Internal Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Genovese’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A52149 · Current
Licensed to practise in California · since 1993 · expires 2028-12-31 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Money from drug and device companies
$99 in 2025
| 2025 | 1 | 1 | None | $99 |
| 2023 | 1 | 7 | None | $1,003 |
| 2022 | 1 | 1 | None | $684 |
| 2020 | 9 | 19 | $172,514 | $172,928 |
| 2019 | 20 | 179 | $198,007 | $229,378 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Eli Lilly and | None | $99 | 1 payment
|
See the published payment
| Eli Lilly and | Education · 2025-04-25 | None | $99 |
See earlier years (2023, 2022, 2020, 2019)
2023: $1,003
| Eli Lilly and | None | $1,003 | 7 payments
|
2022: $684
| Gilead Sciences | None | $684 | 1 payment
|
2020: $172,928
| Gilead Sciences | None | $150,746 | 6 payments
|
| Ucb Sa | None | $8,500 | 3 payments
|
| EMD Serono | None | $5,528 | 1 payment
|
| Eli Lilly and | None | $3,063 | 1 payment
|
| Novartis Pharmaceuticals | Ilaris | $1,765 | 3 payments
|
| Sanofi US Services | None | $1,611 | 1 payment
|
| Amgen | Otezla | $1,599 | 2 payments
|
| Sanofi-Aventis U.S. | Kevzara | $100 | 1 payment
|
| GlaxoSmithKline | None | $16 | 1 payment
|
2019: $229,378
| Gilead Sciences | None | $68,119 | 44 payments
|
| Eli Lilly and | Taltz | $57,510 | 59 payments
|
| Genentech | Non-Covered Product | $17,645 | 3 payments
|
| Novartis Pharma AG | Cosentyx Cosentyx Dermatology | $17,011 | 7 payments
|
| Lilly USA | Taltz | $15,857 | 10 payments
|
| Novartis Pharmaceuticals | Cosentyx | $8,922 | 5 payments
|
| Regeneron Healthcare Solutions | Kevzara | $8,157 | 13 payments
|
| EMD Serono | None | $7,625 | 2 payments
|
| AbbVie | Humira | $7,005 | 15 payments
|
| UCB Biosciences | None | $6,250 | 3 payments
|
| Horizon Therapeutics plc | None | $5,130 | 1 payment
|
| GlaxoSmithKline | None | $4,533 | 4 payments
|
| Genzyme | Kevzara | $2,014 | 2 payments
|
| Samsung Bioepis Co. | Renflexis | $1,200 | 2 payments
|
| Pfizer | Xeljanz | $940 | 1 payment
|
| Aclaris Therapeutics | None | $625 | 1 payment
|
| Amgen | None | $500 | 1 payment
|
| Medexus Pharma | Rasuvo | $164 | 2 payments
|
| Sanofi-Aventis U.S. | Kevzara | $141 | 2 payments
|
| Genentech USA | Actemra | $31 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · A Phase II, Single-Site,Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis · 2019 | Their institution | $47,290 |
| AbbVie, Inc. · 2019 | Their institution | $36,031 |
| EMD Serono, Inc. · Msc2364447c · 2019 | Their institution | $16,099 |
| GlaxoSmithKline, LLC. · A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An · 2020 | Their institution | $13,489 |
| GlaxoSmithKline, LLC. · A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An · 2020 | Their institution | $13,489 |
| Roche Products Limited · Cad11 Mab Ph2a B in Ra A Tnf Ir · 2019 | Their institution | $11,583 |
| AbbVie, Inc. · Rinvoq · 2019 | Their institution | $8,691 |
| GlaxoSmithKline, LLC. · A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An · 2022 | Their institution | $5,233 |
| AbbVie Inc. · Rinvoq · 2020 | Their institution | $4,733 |
| PFIZER INC. · A Longterm Openlabel Extension Study of Tofacitinib Cp690550 for the Treatment of Psoriatic Arthritis · 2019 | Their institution | $3,286 |
| GENZYME CORPORATION · A Multi-Center, Uncontrolled Extension Study Evaluating Efficacy and Safety of Sar153191 on Top of Dmards in Patients With Active Rheumatoid Arthritis (Ra) · 2020 | This clinician | $2,680 |
| Eli Lilly and Company · 2019 | This clinician | $2,350 |
| Eli Lilly and Company · A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study To Evaluate the Safety and Efficacy of Ly3337641 in Adult Subjects With Rheumatoid Arthritis: the Rajuvenate Study · 2019 | Their institution | $2,285 |
| Eli Lilly and Company · A Phase 3 Multicenter Study To Evaluate the Long Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis · 2020 | Their institution | $1,688 |
| Eli Lilly and Company · A Phase 3 Multicenter Study To Evaluate the Long Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis · 2019 | Their institution | $1,603 |
| GENZYME CORPORATION · A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part, Dose Ranging and Confirmatory Study With An Operationally Seamless Design, Evaluating Efficacy and Safety of Sar153191 on Top of · 2020 | This clinician | $1,340 |
| SANOFI-AVENTIS U.S. LLC · Long-Term Safety of Sarilumab in Rheumatoid Arthritis: An Integrated Analysis With Up To 7 Years? Follow-Up · 2019 | This clinician | $1,162 |
| SANOFI-AVENTIS U.S. LLC · Patients Switched To Sarilumab From Adalimumab Achieve Clinically Important Improvements in Disease Activity: Results From Monarch Trial Open-Label Extension · 2019 | This clinician | $1,005 |
| SANOFI-AVENTIS U.S. LLC · Effect of Sarilumab on Glycosylated Hemoglobin in Patients With Rheumatoid Arthritis and Diabetes · 2019 | This clinician | $1,005 |
| Amgen Inc. · Abp 710 Ph3 Ra Multi-Dose Global · 2020 | Their institution | $1,000 |
| SANOFI-AVENTIS U.S. LLC · Mobility-Target Monarch Pooled Subpopulations · 2019 | This clinician | $923 |
| SANOFI-AVENTIS U.S. LLC · Safety, Efficacy and Glycemic Control of Sarilumab Among Patients With Rheumatoid Arthritis and Diabetes · 2019 | This clinician | $923 |
| GENZYME CORPORATION · A Randomized, Double-Blind, Parallel-Group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis · 2020 | This clinician | $893 |
| SANOFI-AVENTIS U.S. LLC · Glucocorticoid Dose Is Progressively Reduced in Patients With Rheumatoid Arthritis Receiving Sarilumab: Results From the Open-Label Extend Study · 2019 | This clinician | $893 |
| SANOFI-AVENTIS U.S. LLC · Efficacy and Safety of Sarilumab in Combination With Csdmards Or As Monotherapy in Subpopulations of Patients With Moderately To Severely Active Rheumatoid Arthritis in Three Phase III Randomized, Con · 2019 | This clinician | $873 |
| SANOFI-AVENTIS U.S. LLC · Interleukin-6 Receptor Blockade Or Tnf Inhibition for Reducing Glycemia in Patients With Ra and Diabetes: Post Hoc Analyses of Three Randomized, Controlled Trials · 2019 | This clinician | $873 |
| SANOFI-AVENTIS U.S. LLC · Long-Term Effect of Sarilumab Plus Methotrexate on Disease Activity, Physical Function, Radiographic Progression, and Safety: A 5-Year Analysis · 2019 | This clinician | $804 |
| SANOFI-AVENTIS U.S. LLC · High Serum Il-6 Predicts Differential Response Between Sarilumab and Adalimumab Or Mtx · 2019 | This clinician | $714 |
| Amgen Inc. · Abp 710 Ph3 Ra Multi-Dose Global · 2019 | Their institution | $666 |
| SANOFI-AVENTIS U.S. LLC · Long-Term Safety and Efficacy of Sarilumab Over 5 Years in Patients With Rheumatoid Arthritis With 1 Or >1 Prior Tumor Necrosis Factor Inhibitor Failures · 2020 | This clinician | $530 |
| SANOFI-AVENTIS U.S. LLC · Association Between Low Hemoglobin and Radiographic Progression Over 52 Weeks in Patients With Rheumatoid Arthritis: Results From A Phase 3 Trial of Sarilumab · 2020 | This clinician | $530 |
| SANOFI-AVENTIS U.S. LLC · Long-Term Safety and Efficacy of Sarilumab Over 5 Years in Patients With Rheumatoid Arthritis Refractory To Tumor Necrosis Factor Inhibitors · 2020 | This clinician | $530 |
| SANOFI-AVENTIS U.S. LLC · Evaluation of Sarilumab (Sar153191/Regn88) on Top of Methotrexate in Rheumatoid Arthritis Patients (Ra-Mobility) · 2019 | This clinician | $424 |
| SANOFI-AVENTIS U.S. LLC · A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part, Dose Ranging and Confirmatory Study With An Operationally Seamless Design, Evaluating Efficacy and Safety of Sar153191 on Top of Methotrexate (Mtx) in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders To Mtx Therapy · 2019 | This clinician | $424 |
| SANOFI-AVENTIS U.S. LLC · High Serum Interleukin-6 Is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Methotrexate Or Adalimumab · 2019 | This clinician | $360 |
| SANOFI-AVENTIS U.S. LLC · Associations Between Rheumatoid Arthritis Disease Activity and Patient-Reported Outcomes in Sarilumab Clinical Trials · 2020 | This clinician | $353 |
| SANOFI-AVENTIS U.S. LLC · Efficacy and Safety of Switching From Adalimumab To Sarilumab in Patients With Rheumatoid Arthiritis: Results of the Monarch Open-Label Extension Study · 2019 | This clinician | $318 |
| SANOFI-AVENTIS U.S. LLC · Efficacy and Safety of Sarilumab in Combination With Csdmards Or As Monotherapy in Subpopulations of Patients With Moderately To Severely Active Rheumatoid Arthritis in Three Phase III Randomized, Con · 2020 | This clinician | $274 |
| SANOFI-AVENTIS U.S. LLC · Interleukin-6 Receptor Blockade Or Tnf Inhibition for Reducing Glycemia in Patients With Ra and Diabetes: Post Hoc Analyses of Three Randomized, Controlled Trials · 2020 | This clinician | $274 |
| SANOFI-AVENTIS U.S. LLC · Long-Term Efficacy With 5-Year-Radiographic Results and Safety of Sarilumab in Combination With Csdmards in Patients With Rheumatoid Arthritis · 2019 | This clinician | $262 |
| SANOFI-AVENTIS U.S. LLC · Long-Term Safety and Efficacy of Sarilumab Plus Methotrexate on Disease Activity, Physical Function and Radiographic Progression: 5 Years of Sarilumab Plus Methotrexate Treatment · 2019 | This clinician | $206 |
| EMD Serono, Inc. · Related To Multiple Studies · 2019 | This clinician | $173 |
| EMD Serono, Inc. · Bavencio · 2019 | Their institution | $75 |
| SANOFI-AVENTIS U.S. LLC · Efficacy and Safety of Switching From Adalimumab To Sarilumab in Patients With Rheumatoid Arthritis: Results of the Monarch Open-Label Extension Study · 2019 | This clinician | $70 |
| SANOFI-AVENTIS U.S. LLC · A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Two-Part, Dose Ranging and Confirmatory Study With An Operationally Seamless Design, Evaluating Efficacy and Safety of Sar153191 on Top of · 2020 | This clinician | $28 |
| SANOFI-AVENTIS U.S. LLC · High Serum Interleukin-6 Is Associated With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab Or Methotrexate in A Post Hoc Analysis · 2020 | This clinician | $28 |
Professional record
- NPI
- 1487711875
- Licence
- CA A52149California A52149: Current · expires 2028-12-31
- Trained
- Johns Hopkins University School of Medicine, 1992
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-01-03
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1000 Welch Rd, Palo Alto, CA, 94304